Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Ann Hum Genet. 2008 Aug 13;72(Pt 6):834–847. doi: 10.1111/j.1469-1809.2008.00469.x

Figure 7.

Figure 7

Genome-wide power comparison between whole genome tag sets designed by our power-optimized method and the commercial products in the CEU population. We measure the power assuming relative risk of 1.2, disease prevalence of 0.01, a 5% genome-wide significance level, and a 5% MAF threshold for causal SNPs. We use 8,000 cases and 8,000 controls when designing the tag sets.